T1	Participants 68 89	in pancreatic cancer:
T2	Participants 403 507	resectable pancreatic cancer patients treated with adjuvant gemcitabine compared with untreated patients
T3	Participants 636 648	observation.
T4	Participants 649 694	Tissue samples of 162 patients were available
T5	Participants 1426 1466	expression in pancreatic cancer patients
